Wedbush Forecasts Rezolute’s FY2025 Earnings (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) – Investment analysts at Wedbush reduced their FY2025 earnings per share (EPS) estimates for shares of Rezolute in a note issued to investors on Tuesday, May 13th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.94) per share for the year, down from their prior forecast of ($0.87). Wedbush has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. Wedbush also issued estimates for Rezolute’s Q4 2025 earnings at ($0.23) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $0.40 EPS.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05).

RZLT has been the subject of a number of other reports. Guggenheim reissued a “buy” rating on shares of Rezolute in a report on Monday, February 10th. JMP Securities increased their price target on Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. Finally, Craig Hallum raised Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and a consensus price target of $12.14.

Rezolute Price Performance

Shares of RZLT stock opened at $3.57 on Friday. Rezolute has a 12-month low of $2.22 and a 12-month high of $6.19. The firm has a market capitalization of $216.11 million, a price-to-earnings ratio of -2.93 and a beta of 1.01. The business has a 50 day simple moving average of $3.24 and a 200 day simple moving average of $4.30.

Insider Buying and Selling at Rezolute

In related news, CEO Nevan C. Elam acquired 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The stock was acquired at an average cost of $2.85 per share, with a total value of $35,060.70. Following the purchase, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. The trade was a 5.81% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Wladimir Hogenhuis acquired 10,000 shares of Rezolute stock in a transaction dated Tuesday, February 18th. The shares were bought at an average cost of $4.70 per share, with a total value of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares in the company, valued at approximately $363,154.90. This represents a 14.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 39,060 shares of company stock valued at $130,694. 18.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rezolute

Several large investors have recently modified their holdings of RZLT. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute during the 1st quarter worth $35,000. JPMorgan Chase & Co. purchased a new stake in shares of Rezolute in the third quarter valued at $42,000. Paloma Partners Management Co purchased a new stake in shares of Rezolute in the first quarter valued at $48,000. Alpine Global Management LLC purchased a new stake in shares of Rezolute in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of Rezolute in the first quarter valued at $95,000. 82.97% of the stock is owned by institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.